Who is sponsoring NCT04874974?

NCT04874974 is sponsored by Max-Planck-Institute of Psychiatry.

What drugs are being tested in NCT04874974?

Interventions in NCT04874974: Metacognitive and Defusion Training.

What condition does NCT04874974 study?

NCT04874974 studies Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder, Shared Psychotic Disorder, Schizoaffective Disorder, Other Psychotic Disorder Not Due to A Substance or Known Physiological Condition, Unspecified Psychosis Not Due to a Substance or Known Physiological Condition, Manic Episode, Severe With Psychotic Symptoms, Bipolar Disorder, Current Episode Manic Severe With Psychotic Features, Bipolar Disorder, Current Episode Depressed, Severe, With Psychotic Features, Major Depressive Disorder, Single Episode, Severe With Psychotic Features, Major Depressive Disorder, Recurrent, Severe With Psychotic Symptoms.

Is NCT04874974 still recruiting?

NCT04874974 is currently completed. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT04874974: PROBAS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Feasibility of a Novel Process-based Treatment for Patients With Psychosis

Completed NA Last updated 23 October 2023

What this trial tests

NA trial testing Metacognitive and Defusion Training in Schizophrenia in 37 participants. Completed in 23 September 2023.

Timeline

10 May 2021

Primary endpoint
10 March 2022

23 September 2023

Quick facts

Lead sponsor	Max-Planck-Institute of Psychiatry
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	10 May 2021
Primary completion	10 March 2022
Estimated completion	23 September 2023
Sites	1 location across Germany

Drugs / interventions tested

Metacognitive and Defusion Training

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Schizotypal Disorder — all drugs for Schizotypal Disorder →
Delusional Disorder — all drugs for Delusional Disorder →
Brief Psychotic Disorder — all drugs for Brief Psychotic Disorder →

Sponsor

Max-Planck-Institute of Psychiatry

Who can join

Adults 18 to 70, any sex, with Schizophrenia or Schizotypal Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Developing a mechanism-based therapy for acute psychiatric inpatients with psychotic symptoms: an Intervention Mapping approach.
Gussmann E, Lucae S, Falkai P, Padberg F, et al · · 2023 · cited 2× · PMID 37324820 · DOI 10.3389/fpsyt.2023.1160075

Verify or expand the search:

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Max-Planck-Institute of Psychiatry trials

Trials by the same sponsor.

NCT07402356 — VR Pupillometry in Cognitive Impairment · recruiting
NCT07022171 — Mechanisms of Transcutaneous Auricular Vagus Nerve Stimulation in Depression · NA · recruiting
NCT06396312 — Deep Phenotyping for Clinical Inferring Response in Treatment Resistant Depression · recruiting
NCT06532097 — Initial Effect Size Estimation of a Smartwatch-based Intervention for Physical and Behavioral Activation in Depressed Pa · completed
NCT05463562 — Multimodal Biomarkers of Electroconvulsive Therapy in Severe and Treatment-resistant Depression · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04874974 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Max-Planck-Institute of Psychiatry
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04874974.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing